Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?

ANI Pharmaceuticals Inc's ANIP third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the consensus of $111.92 million.

Net revenues for generic pharmaceutical products were $63.7 million, up 29.7%, driven by increased volume from the annualization of 2022 launches and a favorable product mix.

Generics, Established Brands and Other reported net sales of $102.1 million, representing year-over-year growth of 43.4%.

Revenues for the lead asset, Cortrophin Gel, reached $29.7 million, up 135.9%, driven by increased volume in this second year of launch. 

Adjusted EPS of $1.27, up from $0.58 a year ago, beat the consensus of $0.84.

The company reported third-quarter adjusted EBITDA of $36.5 million, representing year-over-year growth of 98.3%.

Guidance: For FY23, ANI Pharmaceuticals sees FY23 revenue of $468 million-$478 million versus prior guidance of $425 million-$445 million and the consensus of $452.94 million.

The company forecasts FY23 Adjusted EPS of $4.29-$4.57 versus prior guidance of $3.62-$4.11 and the consensus of $4.08.

The company raised Cortrophin-specific revenue guidance to $100 million-$107 million from $90 million-$100 million.

Price Action: ANIP shares are down 17.10% at $52.75 at publication Wednesday.

Read Next: Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefspharmaceuticalswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!